- Agouron Pharmaceuticals has reported favorable clinical results from Phase I trials of its oral HIV protease inhibitor AG1343. The study showed that two or three times per day dosing achieved sufficient plasma concentrations of the drug to inhibit replication of the virus. The company also reported that animal studies had shown concentrations of the drug in the lymph nodes, a critical reservoir for the virus.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze